The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally (c) ribavirin, and methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient that has genetic variations located near the IL28B gene, including SNP rs12979860 with a CC or non-CC genotype and SNP rs8099917 with a TT or non-TT genotype.
本发明涉及包括(a)本文所述的化合物(1)或其药学上可接受的盐,(b)本文所述的化合物(2)或其药学上可接受的盐,以及可选的(c)
利巴韦林的治疗组合,以及使用这种治疗组合治疗HCV感染或减轻患有位于I
L28B
基因附近的遗传变异的患者的一种或多种症状的方法,包括具有CC或非CC
基因型的SNP rs12979860和具有
TT或非
TT基因型的SNP rs8099917。